Research at Abbvie Inc. and Calico Life Sciences LLC has led to the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) and/or PTPN1B. They are reported to be useful for the treatment of cancer, type 2 diabetes and nonalcoholic steatohepatitis (NASH).
A lot of biosimilar sponsors and wannabes will be watching as the Humira biosimilar competition unfolds in the U.S. While the competition started Jan. 31 with the launch of Amgen Inc.’s Amjevita, the true test of the strength of the competition will come in five months when other adalimumab biosimilars, including Boehringer Ingelheim GmbH’s interchangeable, hit the market.
With at least six others behind it, Amgen Inc.’s Amjevita is leading a 2023 U.S. biosimilars charge to challenge the all-time biggest-selling drug, Humira (adalimumab), from Abbvie Inc. Amjevita hit the U.S. market Jan. 31, and Amgen has the biosimilar priced at two levels, both lower than Humira’s. One is a list price 55% below Humira’s list price of about $115,000 annually and the second is 5% below Humira’s list price. Boehringer Ingelheim GmbH, Sandoz Inc., Samsung Bioepis Co. Ltd./Organon & Co., Pfizer Inc., Viatris Inc. and Coherus Biosciences Inc. all have biosimilar challengers to Humira that are set to launch in July 2023, all likely to come with a lower price tag than Humira’s.
Taking aim at big pharma’s current penchant for acquisition over in-house innovation, Sen. Elizabeth Warren (D-Mass.) is asking the Federal Trade Commission (FTC) to consider the impact a biopharma merger, whether it’s proposed or a done deal, may have on future innovation.
Abbvie Inc. has described new proteolysis targeting chimera (PROTA) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to tyrosine protein phosphatase nonreceptor type 2 (PTPN2)-targeting moiety reported to be useful for the treatment of cancer, diabetes type 2 and nonalcoholic steatohepatitis.
Abbvie Inc. and Eli Lilly and Co. Inc. have pulled out of the U.K.’s voluntary pricing scheme for branded drugs in protest at the 26.5% of their revenues they would be required to pay back to the government in 2023.
Since the advent of COVID-19 mRNA vaccines, the space has steadily grown hotter, a situation on which Anima Biotech Inc. has capitalized by way of a potential $580 million-plus deal with Abbvie Inc. to deploy mRNA biology modulators for three targets across oncology and Immunology.
Abbvie Inc. and Immunome Inc. have announced a worldwide collaboration and option agreement for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's discovery engine.
Facing a 26.5% rebate on 2023 sales of branded prescription drugs in the U.K., the Association of the British Pharmaceutical Industry (ABPI) is seeking talks with the government early in the new year to develop a new biopharma settlement for the future that will reflect the potential of the life sciences sector to drive improvements in the health and economy of the U.K.
The actuary office at CMS reported that U.S. spending on health care grew by a modest rate of 2.7% in 2021, an outcome that would ordinarily prompt cheers by policy wonks who worry about the effect of ever-growing national health expenditures (NHEs) on the larger economy. The problem is that NHE had ballooned by more than 10% in 2020, a rate of growth that was driven in large part by the COVID-19 pandemic, but which statistically overshadowed the growth rate in 2021.
